HISTORY

1909

First clinical analysis laboratory

The hematologist Josep Antoni Grifols i Roig founds a clinical analysis laboratory in Barcelona: the Instituto Central de Análisis Clínicos, Bacteriológicos y Químicos, a precursor to Laboratorios Grifols.

 

1916

First instruments

The difficulty of keeping samples sterile drives Grifols i Roig to develop four different models of clinical analysis flebula, an analytical instrument used for extracting blood samples in aseptic conditions.

 

1928

Pioneers of indirect transfusion

The First World War generates international interest in the science of blood transfusion. In Spain, Grifols i Roig patents the first instrument for carrying out indirect blood transfusions, the transfusion flebula.

 

1940

A postwar family business

The founding of Laboratorios Grifols by Grifols i Roig and his sons, Josep Antoni Grifols i Lucas, a hematologist; and Víctor Grifols i Lucas, a chemist and pharmacist, begins an era of business dedicated to clinical analysis and the preparation of freeze-dried plasma.

 

1945

Hemobanco Grifols is born

Freeze-drying as a technique for improving plasma conservation becomes a reality under the innovative leadership of Víctor Grifols i Lucas. Against this backdrop, he opens the doors to the first private blood and plasma bank in Spain: the Hemobanco of Laboratorios Grifols. 

 

1951

Plasmapheresis, a new method of obtaining plasma

Víctor Grifols i Lucas takes control of innovation and Josep Antoni Grifols i Lucas of Grifols' scientific research. For the first time in the world, the results of a systematic application of the plasmapheresis technique in humans are published in the British Medical Journal. The study, led by Josep Antoni, includes 320 donors and is presented at the 4th International Congress of Blood Transfusion Medicine. 

 

1957

Gri-Cel, a company dedicated to scientific instrumentation

Víctor Grifols i Lucas  and Guillermo Celis found Gri-Cel, a company dedicated to the design and manufacture of laboratory and blood bank instruments, a future pillar of Grifols' growth. 

 

1958

Plasma fractionation begins

Grifols opens its first plasma fractionation plant in Barcelona.

 

1960

First North American partners

Grifols begins a partnership with Dade Reagents, a North American company that manages blood banks in the United States, directed by hematologist John Elliot. Products are sold across Spain under the brand Dade-Grifols.

 

1972

Production increases

Grifols opens a new production plant in Parets del Vallès (Barcelona). The plant includes sections for plasma fractionation, manufacture of parenteral solutions and scientific instrumentation.

 

1987

Grupo Grifols is born

Control of the company is handed down by the entrepreneur Víctor Grifols Roura, a process that finishes in 1987. The holding company Grupo Grifols is created, uniting the commercial company and clinical diagnostic, plasma-derived medicines and parenteral solutions production companies.

 

1988

International expansion begins

Grifols opens its first subsidiary in Portugal, marking the beginning of decades of international expansion.

 

1995

First Food and Drug Administration (FDA) license awarded

With the production plant in Parets del Vallès (Barcelona), Grifols becomes the first Spanish company to receive an FDA license for its installations and a biological product, albumin. 

 

1996

New diagnostic cards

Grifols launches blood-typing cards based on new gel technology.

 

2002

Integration of plasma donation centers

Grifols acquires the company SeraCare, now Biomat, and its 43 plasma donation centers in the United States. 

 

2003

Acquisition of North American assets

Grifols acquires Alpha Therapeutic Corporation-Mitsubishi, including its plasma fractionation plant in Los Angeles (California). 

 

2006

Grifols listed on the Spanish stock exchange

Grifols begins trading on the Spanish stock market. 

 

2008

The IBEX35

Grifols is listed on the IBEX35.

 

2009

The Grifols Academy of Plasmapheresis

The Grifols Academy of Plasmapheresis is launched to train employees in specific disciplines related to the plasma-derivatives industry.

 

2011

A giant leap forward in the plasma industry

With the acquisition of the North American company Talecris Biotherapeutics, Grifols becomes the third largest manufacturer of plasma-derived medicines in the world and begins trading on NASDAQ.

 

2014

Growth of the Diagnostic Division

The acquisition of Novartis' transfusion unit offers integrated solutions across the different processes, from donation to transfusion.

 

2016

Generational handover

Grifols' President and CEO, Víctor Grifols Roura, who took over from Víctor Grifols i Lucas during the 1980s, hands control of the company to his brother Raimon Grifols and his son Víctor Grifols Deu: Grifols' new Chief Executive Officers.

 

2017

Leaders in transfusion medicine

With the acquisition of Hologic's transfusion unit, Grifols investigates, develops and produces reagents and instrumentation based on NAT technology.

 

2018

Acquisition of Haema

The acquisition of German company Haema enables Grifols to diversify and expand its network of plasma donation centers outside the US.

Highlights

Mission

We improve the health and well-being of patients around the world.

Read more

Plasma journey

Grifols plasma medicines are a unique class of biologic therapies that require a lengthy and complex manufacturing process.

Read more

Commitment

We are committed to a long-term vision that creates a sustainable, positive impact on the communities in which we operate.

Read more